Roy Gomez ESA-SRB-APEG-NZSE 2022

Roy Gomez

My main research and areas of interest are in Growth Disorders and GH/IGF-I axis. I have over 20 years of experience in the field of pharmaceutical research and development.

Abstracts this author is presenting:

• Efficacy and safety of once-weekly somatrogon in pediatric subjects with growth hormone deficiency: lack of impact of anti-drug antibodies — ANZSPED (née APEG) Poster Listing: Scientific Abstract
• Efficacy and safety of once-weekly somatrogon vs once-daily Genotropin in Asian subjects: post-hoc subgroup analysis of the pivotal phase 3 study — ANZSPED (née APEG) Poster Listing: Scientific Abstract
• Efficacy of once-weekly somatrogon vs once-daily Genotropin in subjects stratified by peak stimulated growth hormone values (≤3, >3 to ≤6.7, and >6.7 ng/mL): post hoc analysis of the pivotal phase 3 trial — ANZSPED (née APEG) Poster Listing: Scientific Abstract